I find it interesting that a phase one trial would be multiple sites, then the PR goes on to state that they are working on Europe to come on board as well. All this for a phase one and by definition, "test an experimental drug or treatment in a small group of people (20–80) for the first time to evaluate its safety, determine a safe dosage range, and identify side effects."
So, this leads me to believe that either the first single trial site is having unexpected trouble with enrollment or they are so confident that it works, they want to make sure the world knows it with multiple sites reporting the same results as to make sure it's validated. (phase 1 trial results typically have may critics from being a single site with cherry picked results).
As I have said before, the results of Direct will either sink this company or put it on the map as a real player in dendritic cells. There are too many players in the GBM race, if Direct doesn't produce results, I feel it will severely effect NWBO and DCVAX L in a negative way.
There are many different types of cancers they have to treat, so it could take too long for the right ones (that also qualify) to walk through the doors of one site. I don't believe this has anything to do with any results, as multiple sites were in the plans from day 1. Also, the first reporting will be for only the first few patients, and they probably received the smallest dosages, BUT even one positive result on an untreatable cancer is a big deal.
mtaotter - did I hear a Midnight Run reference there? I hope so.